EMA Authorised: Scemblix (asciminib hydrochloride) — Novartis Europharm Limited

View source ↗

Summary

Scemblix (asciminib hydrochloride) has been authorised in the EU for chronic myeloid leukemia positive for BCR-ABL, with orphan designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Leukemia Myelogenous Chronic Bcr-abl Positive

Drugs mentioned

• SCEMBLIX (ASCIMINIB)

Snippet

Status: Authorised. Therapeutic area: Leukemia, Myelogenous, Chronic, BCR-ABL Positive. MAH: Novartis Europharm Limited. Decision date: 25/06/2026. Orphan medicine